330 related articles for article (PubMed ID: 28428708)
1. Indoleamine 2,3-dioxygenase: As a potential prognostic marker and immunotherapeutic target for hepatocellular carcinoma.
Asghar K; Farooq A; Zulfiqar B; Rashid MU
World J Gastroenterol; 2017 Apr; 23(13):2286-2293. PubMed ID: 28428708
[TBL] [Abstract][Full Text] [Related]
2. Human CD14+ CTLA-4+ regulatory dendritic cells suppress T-cell response by cytotoxic T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2,3-dioxygenase production in hepatocellular carcinoma.
Han Y; Chen Z; Yang Y; Jiang Z; Gu Y; Liu Y; Lin C; Pan Z; Yu Y; Jiang M; Zhou W; Cao X
Hepatology; 2014 Feb; 59(2):567-79. PubMed ID: 23960017
[TBL] [Abstract][Full Text] [Related]
3. High Indoleamine 2,3-Dioxygenase Expression along with Low Bridging Integrator-1 Expression in Hepatocellular Carcinoma Patients.
Asghar K; Rana IA; Abubakar M; Hasham K; Tahseen M; Bilal S; Mehmood S; Farooq A; Siddique K; Loya A
Asian Pac J Cancer Prev; 2023 May; 24(5):1591-1600. PubMed ID: 37247278
[TBL] [Abstract][Full Text] [Related]
4. Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma.
Pan K; Wang H; Chen MS; Zhang HK; Weng DS; Zhou J; Huang W; Li JJ; Song HF; Xia JC
J Cancer Res Clin Oncol; 2008 Nov; 134(11):1247-53. PubMed ID: 18438685
[TBL] [Abstract][Full Text] [Related]
5. Immunoactivative role of indoleamine 2,3-dioxygenase in human hepatocellular carcinoma.
Ishio T; Goto S; Tahara K; Tone S; Kawano K; Kitano S
J Gastroenterol Hepatol; 2004 Mar; 19(3):319-26. PubMed ID: 14748880
[TBL] [Abstract][Full Text] [Related]
6. Reprogrammed IDO-Induced Immunosuppressive Microenvironment Synergizes with Immunogenic Magnetothermodynamics for Improved Cancer Therapy.
Wang X; Yan B; Li H; Yuan J; Guo J; Wang S; Dai P; Liu X
ACS Appl Mater Interfaces; 2024 Jun; 16(24):30671-30684. PubMed ID: 38843203
[TBL] [Abstract][Full Text] [Related]
7. [Relationship between the expressions of indoleamine 2, 3-dioxygenase in hepatocellular carcinoma and clinicopathological parameters].
Lin L; Yang DH; Huang Y; Li XH; Zhang QL; Liu X; Liang JK; Zhong KB; He H
Zhonghua Yi Xue Za Zhi; 2013 Jul; 93(28):2186-90. PubMed ID: 24169325
[TBL] [Abstract][Full Text] [Related]
8. Hepatocellular carcinoma-associated fibroblasts trigger NK cell dysfunction via PGE2 and IDO.
Li T; Yang Y; Hua X; Wang G; Liu W; Jia C; Tai Y; Zhang Q; Chen G
Cancer Lett; 2012 May; 318(2):154-61. PubMed ID: 22182446
[TBL] [Abstract][Full Text] [Related]
9. H
Yang D; Li T; Li Y; Zhang S; Li W; Liang H; Xing Z; Du L; He J; Kuang C; Yang Q
J Exp Clin Cancer Res; 2019 Feb; 38(1):88. PubMed ID: 30777103
[TBL] [Abstract][Full Text] [Related]
10. Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma.
Brown ZJ; Yu SJ; Heinrich B; Ma C; Fu Q; Sandhu M; Agdashian D; Zhang Q; Korangy F; Greten TF
Cancer Immunol Immunother; 2018 Aug; 67(8):1305-1315. PubMed ID: 29959458
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy of hepatocellular carcinoma.
Korangy F; Höchst B; Manns MP; Greten TF
Expert Rev Gastroenterol Hepatol; 2010 Jun; 4(3):345-53. PubMed ID: 20528121
[TBL] [Abstract][Full Text] [Related]
12. Review of 10 years of research on breast cancer patients: Focus on indoleamine 2,3-dioxygenase.
Asghar K; Farooq A; Zulfiqar B; Loya A
World J Clin Oncol; 2021 Jun; 12(6):429-436. PubMed ID: 34189067
[TBL] [Abstract][Full Text] [Related]
13. Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy.
Sun C; Sun HY; Xiao WH; Zhang C; Tian ZG
Acta Pharmacol Sin; 2015 Oct; 36(10):1191-9. PubMed ID: 26073325
[TBL] [Abstract][Full Text] [Related]
14. Aberrant Upregulation of Indoleamine 2,3-Dioxygenase 1 Promotes Proliferation and Metastasis of Hepatocellular Carcinoma Cells via Coordinated Activation of AhR and β-Catenin Signaling.
Chen CT; Wu PH; Hu CC; Nien HC; Wang JT; Sheu JC; Chow LP
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769098
[TBL] [Abstract][Full Text] [Related]
15. Liver-infiltrating CD8(+) lymphocytes as prognostic factor for tumour recurrence in hepatitis C virus-related hepatocellular carcinoma.
Ramzan M; Sturm N; Decaens T; Bioulac-Sage P; Bancel B; Merle P; Tran Van Nhieu J; Slama R; Letoublon C; Zarski JP; Jouvin-Marche E; Marche PN; Leroy V
Liver Int; 2016 Mar; 36(3):434-44. PubMed ID: 26215124
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of indoleamine 2,3-dioxygenase activity and expression in nasopharyngeal carcinoma.
Ben-Haj-Ayed A; Moussa A; Ghedira R; Gabbouj S; Miled S; Bouzid N; Tebra-Mrad S; Bouaouina N; Chouchane L; Zakhama A; Hassen E
Immunol Lett; 2016 Jan; 169():23-32. PubMed ID: 26608400
[TBL] [Abstract][Full Text] [Related]
17. Mechanism and prognostic value of indoleamine 2,3-dioxygenase 1 expressed in hepatocellular carcinoma.
Li S; Han X; Lyu N; Xie Q; Deng H; Mu L; Pan T; Huang X; Wang X; Shi Y; Zhao M
Cancer Sci; 2018 Dec; 109(12):3726-3736. PubMed ID: 30264546
[TBL] [Abstract][Full Text] [Related]
18. Indoleamine 2,3-dioxygenase promotes peritoneal metastasis of ovarian cancer by inducing an immunosuppressive environment.
Tanizaki Y; Kobayashi A; Toujima S; Shiro M; Mizoguchi M; Mabuchi Y; Yagi S; Minami S; Takikawa O; Ino K
Cancer Sci; 2014 Aug; 105(8):966-73. PubMed ID: 24826982
[TBL] [Abstract][Full Text] [Related]
19. Indoleamine 2,3-dioxygenase (IDO): Biology and Target in Cancer Immunotherapies.
Selvan SR; Dowling JP; Kelly WK; Lin J
Curr Cancer Drug Targets; 2016; 16(9):755-764. PubMed ID: 26517538
[TBL] [Abstract][Full Text] [Related]
20. Tumoral indoleamine 2, 3-dioxygenase 1 is regulated by monocytes and T lymphocytes collaboration in hepatocellular carcinoma.
Zhao Q; Wang PP; Huang ZL; Peng L; Lin C; Gao Z; Su S
Oncotarget; 2016 Mar; 7(12):14781-90. PubMed ID: 26895379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
